Estradiol/drospirenone
{{Short description|Combination drug}}
{{Drugbox
| image = Estradiol.svg
| width = 225px
| caption = Estradiol
| image2 = Drospirenone.svg
| width2 = 235px
| caption2 = Drospirenone
| type = combo
| drug_name = Estradiol/drospirenone
| component1 = Estradiol
| class1 = Estrogen
| component2 = Drospirenone
| class2 = Progestogen; Progestin; Antimineralocorticoid; Antiandrogen
| tradename = Angeliq
| Drugs.com =
| MedlinePlus =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US = Rx-only
| routes_of_administration = By mouth
| class = Estrogen; Progestin; Progestogen; Antimineralocorticoid; Antiandrogen
| CAS_number = 350818-73-4
| ATC_prefix =
| ATC_suffix =
| PubChem =
| DrugBank =
| synonyms = E2/DRSP; BAY-864891
}}
Estradiol/drospirenone (E2/DRSP), sold under the brand name Angeliq, is a combination of estradiol (E2), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used in menopausal hormone therapy, specifically the treatment of menopausal syndrome and osteoporosis, in postmenopausal women.{{cite web | title = ANGELIQ (drospirenone and estradiol) Prescribing Information | date = February 2012 | work = Bayer HealthCare Pharmaceuticals Inc. | publisher = U.S. Food and Drug Administration | url = https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021355s003lbl.pdf}}{{Cite web|url=https://adisinsight.springer.com/drugs/800014148|title=Estradiol/Drospirenone - Bayer HealthCare Pharmaceuticals | work = AdisInsight | publisher = }}{{cite journal | vauthors = Rosano GM, Vitale C, Marazzi G, Volterrani M | title = Menopause and cardiovascular disease: the evidence | journal = Climacteric | volume = 10 | issue = Suppl 1 | pages = 19–24 | date = February 2007 | pmid = 17364594 | doi = 10.1080/13697130601114917 | s2cid = 7305124 }} It is taken by mouth and contains 0.5 to 1 mg E2 and 0.25 to 0.5 mg DRSP per tablet. The medication was approved in the United States in 2005. It is marketed widely throughout the world.{{Cite web|url=https://www.drugs.com/ppa/drospirenone-and-estradiol.html#warnings |title = Drospirenone and Estradiol: Uses, Side Effects & Warnings}}
See also
References
{{Reflist}}
External links
- [https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021355s003lbl.pdf Angeliq (estradiol/drospirenone) FDA Label]
- [https://adisinsight.springer.com/drugs/800014148 Estradiol/drospirenone (Angeliq) - AdisInsight]
{{Navboxes
| title = Medical uses
| titlestyle = background:#ccccff
| list1 =
{{Estrogens and antiestrogens}}
{{Progestogens and antiprogestogens}}
{{Mineralocorticoids and antimineralocorticoids}}
{{Androgens and antiandrogens}}
}}
{{Navboxes
| title = Pharmacodynamics
| titlestyle = background:#ccccff
| list1 =
{{Androgen receptor modulators}}
{{Estrogen receptor modulators}}
{{Mineralocorticoid receptor modulators}}
{{Progesterone receptor modulators}}
}}
Category:Combined estrogen–progestogen formulations
Category:Drugs developed by Bayer
{{Genito-urinary-drug-stub}}